Hartford Funds Management Co LLC Has $343,000 Holdings in Danaher Co. (NYSE:DHR)

Hartford Funds Management Co LLC grew its position in shares of Danaher Co. (NYSE:DHR) by 5.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,484 shares of the conglomerate’s stock after buying an additional 76 shares during the quarter. Hartford Funds Management Co LLC’s holdings in Danaher were worth $343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. BKM Wealth Management LLC bought a new stake in Danaher in the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter worth $29,000. OFI Invest Asset Management acquired a new position in Danaher during the third quarter worth $30,000. Rakuten Securities Inc. bought a new position in Danaher during the fourth quarter valued at about $36,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher in the fourth quarter worth about $41,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR traded down $0.16 on Tuesday, reaching $246.66. 3,940,969 shares of the stock traded hands, compared to its average volume of 2,785,271. The firm has a market cap of $182.70 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 3.80 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The stock’s 50-day moving average price is $248.78 and its 200-day moving average price is $231.79. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the company posted $2.36 EPS. The business’s revenue was down 2.6% on a year-over-year basis. Equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were paid a dividend of $0.27 per share. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DHR. Citigroup increased their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. TD Cowen boosted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $269.64.

Insider Activity

In related news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 106,565 shares of company stock worth $26,641,364. Company insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.